3 results
This multicentre phase III study is designed to assess the efficacy and safety of recombinant versus E-Coli derived Aaparaginase from Medac, during treatment of children with newly diagnosed ALL according to the DCOG ALL-10 protocol.Futhermore: To…
This non-controlled multicentric phase II study is designed to assess the safety and to describe (in relation to children of higher age) the pharmacodynamics of recombinant ASNase for first-line treatment of infants (< 1 year of age at…
Primary* To characterize the dynamics of viral clearance (incl. viral cultures, qPCR, antigen clearance) following ensovibep administration * To characterize the serum pharmacokinetics of two single i.v. flat dose levels of ensovibep in patients…